LV11784B - Fibrin-specific antibody for use as an antithrombotic agent - Google Patents

Fibrin-specific antibody for use as an antithrombotic agent Download PDF

Info

Publication number
LV11784B
LV11784B LVP-96-379A LV960379A LV11784B LV 11784 B LV11784 B LV 11784B LV 960379 A LV960379 A LV 960379A LV 11784 B LV11784 B LV 11784B
Authority
LV
Latvia
Prior art keywords
fibrin
fibrinogen
antibody
monoclonal antibody
quot
Prior art date
Application number
LVP-96-379A
Other languages
English (en)
Latvian (lv)
Other versions
LV11784A (lv
Inventor
Paul E Gargan
Original Assignee
American Biogenetic Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Biogenetic Sciences filed Critical American Biogenetic Sciences
Publication of LV11784A publication Critical patent/LV11784A/xx
Publication of LV11784B publication Critical patent/LV11784B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-96-379A 1994-02-24 1996-09-23 Fibrin-specific antibody for use as an antithrombotic agent LV11784B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/204,015 US5487892A (en) 1994-02-24 1994-02-24 Method for treating thrombotic disease using a fibrin specific monoclonal antibody
PCT/US1995/001825 WO1995022986A1 (en) 1994-02-24 1995-02-21 Fibrin-specific antibody for use as an antithrombotic agent

Publications (2)

Publication Number Publication Date
LV11784A LV11784A (lv) 1997-06-20
LV11784B true LV11784B (en) 1997-12-20

Family

ID=22756260

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-96-379A LV11784B (en) 1994-02-24 1996-09-23 Fibrin-specific antibody for use as an antithrombotic agent

Country Status (26)

Country Link
US (1) US5487892A (es)
EP (1) EP0749320A4 (es)
JP (1) JPH09509429A (es)
KR (1) KR970701063A (es)
CN (1) CN1146157A (es)
AU (1) AU708897B2 (es)
BG (1) BG62476B1 (es)
BR (1) BR9506949A (es)
CA (1) CA2183953A1 (es)
CZ (1) CZ246496A3 (es)
FI (1) FI963288A0 (es)
GE (1) GEP20002257B (es)
HU (1) HUT76536A (es)
LT (1) LT4192B (es)
LV (1) LV11784B (es)
MD (1) MD1521G2 (es)
MX (1) MX9603602A (es)
NO (1) NO963497L (es)
NZ (1) NZ281481A (es)
PL (1) PL316005A1 (es)
RU (1) RU2152801C2 (es)
SG (1) SG53279A1 (es)
SK (1) SK108496A3 (es)
TJ (1) TJ301B (es)
UA (1) UA41984C2 (es)
WO (1) WO1995022986A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5453359A (en) * 1988-06-13 1995-09-26 American Biogenetic Sciences, Inc. Immunoassay and kit for in vitro detection of soluble DesAABB fibrin polymers
US5817768A (en) * 1995-06-07 1998-10-06 The New York Blood Center, Inc. Monospecific antibodies against a subunit of fibrinogen
US6727102B1 (en) 1997-06-20 2004-04-27 Leuven Research & Development Vzw Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins
US6309888B1 (en) 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
IL134828A0 (en) * 2000-03-01 2001-05-20 Eship 4U Com Inc System for delivery and receipt of dispatches especially useful for e-commerce
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
CN101087877B (zh) * 2004-12-28 2012-08-08 第一化学药品株式会社 抗人可溶性血纤蛋白单克隆抗体及使用该抗体的免疫学测定方法
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
PL2900277T3 (pl) 2012-12-13 2022-05-16 Immunomedics, Inc. Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
CN110563258A (zh) * 2019-09-06 2019-12-13 广东石油化工学院 一种猪场废水厌氧产氢与达标排放处理方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
US4916070A (en) * 1986-04-14 1990-04-10 The General Hospital Corporation Fibrin-specific antibodies and method of screening for the antibodies
EP0241907A3 (en) * 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
WO1988001514A1 (en) * 1986-08-25 1988-03-10 American Biogenetic Sciences, Inc. Monoclonal antibodies to fibrin
DE3701812A1 (de) * 1987-01-22 1988-08-04 Max Planck Gesellschaft Fibrinspezifischer antikoerper, verfahren zur seiner herstellung und seine verwendung
US5091512A (en) * 1988-06-13 1992-02-25 American Biogenetic Sciences, Inc. Fibrinogen-specific monoclonal antibody
US5223410A (en) * 1988-06-13 1993-06-29 American Biogenetic Sciences, Inc. Method for production of antibodies utilizing an antigen-free animal
WO1989012690A1 (en) * 1988-06-13 1989-12-28 American Biogentic Sciences, Inc. Method for the production of monoclonal antibodies utilizing a germfree animal
US5120834A (en) * 1988-06-13 1992-06-09 American Biogenetic Sciences, Inc. Fibrin-specific monoclonal antibody
US5206140A (en) 1988-06-24 1993-04-27 Research Corporation Technologies, Inc. Assay for soluble crosslinked fibrin polymers
CA2052283A1 (en) * 1990-09-27 1992-03-28 Edgar Haber Recombinant hybrid immunoglobulin molecules and method of use

Also Published As

Publication number Publication date
MX9603602A (es) 1997-05-31
PL316005A1 (en) 1996-12-23
MD1521F2 (en) 2000-08-31
BG100863A (en) 1997-08-29
BG62476B1 (bg) 1999-12-30
LV11784A (lv) 1997-06-20
AU708897B2 (en) 1999-08-12
FI963288A (fi) 1996-08-23
CZ246496A3 (en) 1997-04-16
JPH09509429A (ja) 1997-09-22
LT4192B (en) 1997-07-25
SK108496A3 (en) 1997-10-08
HU9602337D0 (en) 1996-10-28
GEP20002257B (en) 2000-10-25
CN1146157A (zh) 1997-03-26
SG53279A1 (en) 1998-09-28
NO963497D0 (no) 1996-08-22
TJ301B (en) 2001-08-06
CA2183953A1 (en) 1995-08-31
BR9506949A (pt) 1997-09-23
NO963497L (no) 1996-10-16
FI963288A0 (fi) 1996-08-23
LT96140A (en) 1997-03-25
RU2152801C2 (ru) 2000-07-20
MD1521G2 (ro) 2001-03-31
KR970701063A (ko) 1997-03-17
UA41984C2 (uk) 2001-10-15
NZ281481A (en) 1998-07-28
EP0749320A4 (en) 1997-06-18
US5487892A (en) 1996-01-30
AU1843495A (en) 1995-09-11
EP0749320A1 (en) 1996-12-27
HUT76536A (en) 1997-09-29
WO1995022986A1 (en) 1995-08-31
MD960334A (en) 1997-09-30

Similar Documents

Publication Publication Date Title
US20200129600A1 (en) Combination therapy using a factor xii inhibitor and a c-1 inhibitor
US7754215B2 (en) Antithrombotic therapy with antibodies binding to the A3 domain of von Willebrand factor (VWF)
JP6705785B2 (ja) トロンビン結合性抗体分子及びその使用
US5487892A (en) Method for treating thrombotic disease using a fibrin specific monoclonal antibody
PT975672E (pt) Anticorpos para inibir a coagulação sanguínea e métodos para a sua utilização
JPH06502307A (ja) 血液凝固タンパク質のアンタゴニストおよびその利用方法
US6020181A (en) Inhibition of thrombus formation by medical related apparatus comprising treating with fibrinolytic matrix metalloproteinase
JP6894993B2 (ja) 血漿タンパク質にコンジュゲートしたヘパリンを含む治療用ａｐａｃ分子
US5922322A (en) Fibrin(ogen) degradation and clot lysis by fibrinolytic matrix metalloproteinase
US20090010934A1 (en) Cell lines, ligands and antibody fragments for use in pharmaceutical compositions for preventing and treating haemostasis disorders
BANG Physiology and biochemistry of fibrinolysis
JPH03504717A (ja) 血餅溶解の促進のための組成物及び方法
EP1060747A2 (en) Fibrin(ogen) degradation and clot lysis by fibrinolytic metalloproteinase
WO1997002291A1 (en) Method of producing fibrin-specific antibodies using soluble fibrin polymers as an immunogen
Harrington et al. Clinical development of bivalirudin
Prentice Abnormal Haemostasis as Risk Factor and Predictor of Vascular Occlusions